

PRESS RELEASE 2020/09/23

IMMUNETHEP ADDRESSES COVID-19

Immunetep is a biotech company focused on the development of immunotherapies that aim to restore the ability of host immune system to fight infections without contributing for Antimicrobial Resistance as current antibiotics do.

The main focus of Immunetep has been the development a broad-spectrum antibacterial vaccine that is now ready to start human clinical trials.

With the breakout of the Covid-19 pandemic, Immunetep decided to put its capabilities and knowledge to find new solutions that could help to stop this disease. We are addressing Covid-19 twofold:

1) The knowledge gathered with the process of vaccine development allows us to start the assays for the development of a COVID-19 vaccine. This vaccine is designed to potentiate lung immunity to the virus. This vaccine has a dual action. It aims to induce the production of specific anti-SARS-CoV-2 neutralizing antibodies and also to enhance our natural ability to fight viral infections.

2) Recent evidences show that up to 50% of fatal cases associated with SARS-CoV-2 infection are due to opportunistic infections caused by multi-drug resistant bacteria. Taking in account that vaccinating those patients for SARS-CoV-2 wouldn't produce a timely effective response, Immunetep is developing a monoclonal antibody-based therapy to treat these opportunistic bacterial infections.

On the one hand, the vaccine will allow the prevention of disease and avoid human-to-human transmission and, on the other hand, the monoclonal antibodies will ameliorate the symptoms of already infected patients that could reduce significantly the number of fatal cases amongst the COVID-19 patients.